UPTRAVI® (selexipag) is an oral selective prostacyclin (IP) receptor agonist that is distinct from prostacyclin and its analogues, with a higher selectivity for the IP receptor vs other prostanoid receptors. Stimulation of the IP receptor by UPTRAVI® and its active metabolite leads to vasodilatory as well as anti-proliferative and anti-fibrotic effects.
UPTRAVI® was approved by the European Medicines Agency (EMA) in 2016 for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with World Health Organization (WHO) functional class (FC) II–III. UPTRAVI® can be used as either a combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type-5 inhibitor (PDE-5i), or as monotherapy in patients who cannot tolerate these medications. Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease.
Based on pre-clinical, clinical and real-world experience
*As measured by a composite primary morbidity-mortality endpoint. Results were driven by a decrease in disease progression and hospitalisations due to PAH; they do not apply to mortality on its own.
Proactively initiating UPTRAVI® early can give your patients more time.
UPTRAVI® can help your patients with PAH achieve and maintain a low-risk status.
Adding UPTRAVI® in triple combination therapy provides benefits for your patients with PAH.
UPTRAVI® can provide beneficial long-term outcomes for a broad range of patients with PAH.
In the GRIPHON trial, UPTRAVI® patients were 69% more likely to increase their number of low-risk criteria vs placebo.*‡
*Post hoc analysis assessing whether treatment with UPTRAVI® improved risk profile from baseline compared with placebo in the GRIPHON population using the non-invasive French approach and REVEAL 2.0.
‡Change in number of low-risk criteria over time in the non-invasive French risk assessment subgroup (OR 1.69; 95% CI: 1.28–2.24; p=0.0002).
In the real-world SPHERE registry, 85% of patients improved or maintained their baseline risk status after 1 year.*‡
*From the first 250 patients enrolled in SPHERE, an ongoing US-based observational registry of UPTRAVI®-treated patients with PAH.
‡Based on patients who had risk assessment at both baseline and 1 year (196 patients or 78% of the total population).
The overall treatment goal in PAH is to achieve a low-risk status, which is shown to be prognostic for better long-term outcomes.
UPTRAVI® has a well-characterised and generally manageable safety profile.
Adding UPTRAVI® is recommended at the first sign of intermediate risk.
Learn about the patient profiles identified as benefiting from early UPTRAVI® initiation.
Built on ground-breaking innovation and an unwavering commitment to patients, we have created a range of therapeutic solutions to support patients throughout their PAH journey.
CI, confidence interval; EMA, European Medicines Agency; ERA, endothelin receptor antagonist; ERS, European Respiratory Society; ESC, European Society of Cardiology FC, functional class; FDA, Food and Drug Administration; HR, hazard ratio; IP, prostacyclin; OR, odds ratio; PAH, pulmonary arterial hypertension; PDE-5i, phosphodiesterase type-5 inhibitor; WHO, World Health Organization
CP-220222 | May 2021